Quarterly ResultAug 11, 2026, 07:37 AM
Organigram Q3 Net Income $105.5M; Revenue +49% to $105.8M
AI Summary
Organigram Global Inc. reported a significant increase in net income to $105.5 million for Q3 Fiscal 2026, compared to a net loss of $6.3 million in the prior year, primarily driven by a $105.8 million fair value gain on Preferred Shares. Net revenue grew 49% to $105.8 million, largely due to the acquisition of Sanity Group in April 2026, which boosted international medical sales. The company also achieved a 136% increase in Adjusted EBITDA to $13.4 million and maintained its #1 market share in Canadian recreational cannabis. However, Organigram is pausing its US hemp-derived THC business due to upcoming regulatory changes.
Key Highlights
- Q3 Fiscal 2026 net income was $105.5 million, up from a $6.3 million loss in Q3 Fiscal 2025.
- Net revenue increased 49% to $105.8 million in Q3 Fiscal 2026, driven by Sanity Group acquisition.
- Adjusted EBITDA rose 136% to $13.4 million in Q3 Fiscal 2026, reflecting improved gross margin.
- Acquired Sanity Group in April 2026, establishing a significant European cannabis platform.
- Held #1 market share in Canadian recreational cannabis market as of June 2026.
- Pausing US hemp-derived THC business due to new regulatory restrictions effective November 2026.
- Fiscal 2026 net revenue expected to exceed $350 million, with positive free cash flow in Q4.
Price Impact
More from OGI